Purushotham Guroji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Purushotham Guroji has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Craig A. Elmets
Department of Dermatology, University of Alabama at Birmingham
3 shared publicationsIsrar Ahmad
Department of Dermatology, University of Alabama at Birmingham
3 shared publications- Mohammad Athar
UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3 shared publications - Muhammad Shahid Mukhtar
Department of Genetics & Biochemistry, Clemson University, 105 Collings St., Biosystems Research Complex, Clemson, SC 29634, USA
3 shared publications - Nabiha Yusuf
Department of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3 shared publications - Ritesh Kumar Srivastava
UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3 shared publications
Latest Publications
- 7 July 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 61 (8)
Cover Image, Volume 61, Issue 8
- 7 July 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 61 (8)
Cover Image, Volume 61, Issue 8
- 26 April 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 61 (8) , 737-751
Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism
Aberrant activation of multiple complex signaling pathways underlies the pathogenesis of rhabdomyosarcoma (RMS), which remains a cause of mortality in approximately 30% of children with RMS. Bromodomain and extraterminal (BET) domain chromatin remodeling regulates several of these pathways. Here, we targeted bromodomain 4 (BRD4) in combination with another molecular metabolic tumor driver, the Akt/mTOR signaling pathway, to provide a highly effective treatment for this neoplasm. We demonstrated that a nexus of these two molecular pathways underlies RMS pathogenesis. Our data show that the combined inhibition of the BET bromodomain and mTORC1/2 signaling abrogates aggressive RMS growth. Thus, the bromodomain inhibitor RVX‐208 significantly augmented the therapeutic effects of the dual mTORC1/2 inhibitors, OSI‐027 and PP242, both in vitro and in a human xenograft murine model. Drug‐treated residual tumors showed a decrease in the activation of underlying signaling mechanisms characterized by a reduction in the expression of p‐AKT, p‐mTOR, p‐p70S6K, cyclin D1, and proliferation. Our ChIP‐seq data demonstrated that RVX‐208 effectively blocked BRD4 occupancy on its target promoters. ChIP‐qPCR assays further confirmed that RVX‐208 treatment resulted in a significant decrease in H3K27ac and H4K8ac signals at their target loci. While single RVX‐208 treatment induces apoptosis and a single mTORC1/2 inhibitor induces macropinocytosis, their combined treatment led to necroptosis‐mediated cell death. These data suggest that combined treatment with drugs targeting BRD4 and mTORC1/2 may be an effective therapeutic intervention for drug‐resistant RMS.
- 26 April 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 61 (8) , 737-751
Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism
Aberrant activation of multiple complex signaling pathways underlies the pathogenesis of rhabdomyosarcoma (RMS), which remains a cause of mortality in approximately 30% of children with RMS. Bromodomain and extraterminal (BET) domain chromatin remodeling regulates several of these pathways. Here, we targeted bromodomain 4 (BRD4) in combination with another molecular metabolic tumor driver, the Akt/mTOR signaling pathway, to provide a highly effective treatment for this neoplasm. We demonstrated that a nexus of these two molecular pathways underlies RMS pathogenesis. Our data show that the combined inhibition of the BET bromodomain and mTORC1/2 signaling abrogates aggressive RMS growth. Thus, the bromodomain inhibitor RVX‐208 significantly augmented the therapeutic effects of the dual mTORC1/2 inhibitors, OSI‐027 and PP242, both in vitro and in a human xenograft murine model. Drug‐treated residual tumors showed a decrease in the activation of underlying signaling mechanisms characterized by a reduction in the expression of p‐AKT, p‐mTOR, p‐p70S6K, cyclin D1, and proliferation. Our ChIP‐seq data demonstrated that RVX‐208 effectively blocked BRD4 occupancy on its target promoters. ChIP‐qPCR assays further confirmed that RVX‐208 treatment resulted in a significant decrease in H3K27ac and H4K8ac signals at their target loci. While single RVX‐208 treatment induces apoptosis and a single mTORC1/2 inhibitor induces macropinocytosis, their combined treatment led to necroptosis‐mediated cell death. These data suggest that combined treatment with drugs targeting BRD4 and mTORC1/2 may be an effective therapeutic intervention for drug‐resistant RMS.
- 9 August 2021
- Published by Level Up Business Center in Journal of Evidence Based Medicine and Healthcare
- Vol. 8 (32) , 2956-2961
A Prospective Study on Analysis of Histopathological Variations in Post Cholecystectomy Specimens Done for Benign Conditions in a Tertiary Care Hospital, Tirupati
BACKGROUND Cholecystectomy is a common surgical procedure done worldwide for both benign and neoplastic conditions. Cholecystectomy for benign conditions is performed based on clinical signs, symptoms, Ultrasound, CT. Hence there is fair chance of missing early malignant lesions like carcinoma-in-situ and other early carcinomas. Aim: The aim of the study is to analyse histopathological variations in post cholecystectomy specimens done for benign lesions. METHODS The study was conducted in Department of General Surgery, SVRRGGH, Tirupati, for a period of one year, from March 2019 to April 2020. This is a prospective Study conducted among 100 Patients, conducted over a period of one year from time of IEC approval from March 2019 to April 2020. All patients who underwent cholecystectomy for benign biliary disease and gall stone were included in the study. All patients with pre-diagnosed empyema gallbladder, gallbladder malignancy, gallbladder mass, and gallstones associated with obstructive jaundice are excluded from the study. RESULTS In our study, 100 cases of gall bladder disease were studied in the age group of 18 – 70 years, for a period of 1 year from March 2019 in the department of General surgery, SVRRGGH. Occurrence is high in patients of age group 18 – 45 years (65 %). The male to female ratio is 0.5:1 with female preponderance. The most common histopathologic finding was chronic calculus cholecystitis (59 %).Adenocarcinoma of gall bladder (2 %) of the cases with no preoperative suspicion of malignancy. CONCLUSIONS The occurrence of Incidental GBC found in my study is 2 %. Due to high estimate of residual disease, re-resection is still a curative option and is to be considered for pT2 & pT3, but not CBD removal. Prognosis usually is dismal, and five-year survival rates have been reported to be less than 5 % for more advanced stages. KEYWORDS Histopathology, Variations, Cholecystectomy, Specimen, Benign
- 9 August 2021
- Published by Level Up Business Center in Journal of Evidence Based Medicine and Healthcare
- Vol. 8 (32) , 2956-2961
A Prospective Study on Analysis of Histopathological Variations in Post Cholecystectomy Specimens Done for Benign Conditions in a Tertiary Care Hospital, Tirupati
BACKGROUND Cholecystectomy is a common surgical procedure done worldwide for both benign and neoplastic conditions. Cholecystectomy for benign conditions is performed based on clinical signs, symptoms, Ultrasound, CT. Hence there is fair chance of missing early malignant lesions like carcinoma-in-situ and other early carcinomas. Aim: The aim of the study is to analyse histopathological variations in post cholecystectomy specimens done for benign lesions. METHODS The study was conducted in Department of General Surgery, SVRRGGH, Tirupati, for a period of one year, from March 2019 to April 2020. This is a prospective Study conducted among 100 Patients, conducted over a period of one year from time of IEC approval from March 2019 to April 2020. All patients who underwent cholecystectomy for benign biliary disease and gall stone were included in the study. All patients with pre-diagnosed empyema gallbladder, gallbladder malignancy, gallbladder mass, and gallstones associated with obstructive jaundice are excluded from the study. RESULTS In our study, 100 cases of gall bladder disease were studied in the age group of 18 – 70 years, for a period of 1 year from March 2019 in the department of General surgery, SVRRGGH. Occurrence is high in patients of age group 18 – 45 years (65 %). The male to female ratio is 0.5:1 with female preponderance. The most common histopathologic finding was chronic calculus cholecystitis (59 %).Adenocarcinoma of gall bladder (2 %) of the cases with no preoperative suspicion of malignancy. CONCLUSIONS The occurrence of Incidental GBC found in my study is 2 %. Due to high estimate of residual disease, re-resection is still a curative option and is to be considered for pT2 & pT3, but not CBD removal. Prognosis usually is dismal, and five-year survival rates have been reported to be less than 5 % for more advanced stages. KEYWORDS Histopathology, Variations, Cholecystectomy, Specimen, Benign
- Open Access
- 1 July 2021
- Published by Elsevier in Redox Biology
- Vol. 43, 101998
LPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species
- 1 July 2021
- Published by Elsevier in Redox Biology
- Vol. 43, 101998
Open AccessLPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species
- 21 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 742-753.e10
5′-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma
- 21 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 742-753.e10
5′-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma
- Open Access
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (10) , 983-989
Association of Vitamin D Receptor Polymorphisms With the Risk of Nonmelanoma Skin Cancer in Adults
More than 3.5 million new diagnoses of nonmelanoma skin cancer (NMSC) are reported by 2 million Americans each year.1 While the prevalence of cutaneous squamous cell carcinoma (SCC) is only about 16% of all skin cancers, SCC can metastasize, killing 4000 to 8000 people each year.2 Basal cell carcinoma (BCC) is the most common skin cancer and can be highly disfiguring if left untreated. Furthermore, advanced BCC contributes to 3000 deaths annually in the United States. Recent studies have reported that NMSC is the fifth most costly cancer to treat in the Medicare population.3
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (10) , 983-989
Open AccessAssociation of Vitamin D Receptor Polymorphisms With the Risk of Nonmelanoma Skin Cancer in Adults
More than 3.5 million new diagnoses of nonmelanoma skin cancer (NMSC) are reported by 2 million Americans each year.1 While the prevalence of cutaneous squamous cell carcinoma (SCC) is only about 16% of all skin cancers, SCC can metastasize, killing 4000 to 8000 people each year.2 Basal cell carcinoma (BCC) is the most common skin cancer and can be highly disfiguring if left untreated. Furthermore, advanced BCC contributes to 3000 deaths annually in the United States. Recent studies have reported that NMSC is the fifth most costly cancer to treat in the Medicare population.3
- 18 April 2017
- Published by Wiley in Experimental Dermatology
- Vol. 26 (11) , 1018-1025
Loss of INK4a/Arf gene enhances ultraviolet radiation‐induced cutaneous tumor development
The CDKN2A locus encodes for tumor suppressor genes p16INK4a and p14Arf which are frequently inactivated in human skin tumors. The purpose of this study was to determine the relationship between loss of INK4a/Arf activity and inflammation in the development of ultraviolet (UV) radiation‐induced skin tumors. Panels of INK4a/Arf‐/− mice and wild‐type (WT) mice were treated with a single dose of UVB (200 mJ/cm2). For long‐term studies, these mice were irradiated with UVB (200 mJ/cm2) three times weekly for 30 weeks. At the end of the experiment, tissues were harvested from mice and assayed for inflammatory biomarkers and cytokines. A single dose of UVB resulted in a significant increase in reactive oxygen species (ROS) and 8‐dihydroxyguanosine (8‐oxo‐dG) lesions in INK4a/Arf−/− mice compared to WT mice. When subjected to chronic UVB, we found that 100% of INK4a/Arf−/‐ mice had tumors, whereas there were no tumors in WT controls after 24 weeks of UVB exposure. The increase in tumor development correlated with a significant increase in nuclear factor (NF)‐κB, cyclooxygenase‐2 (COX‐2), prostaglandin E2 (PGE2) and its receptors both in UVB‐exposed skin and in the tumors. A significant increase was seen in inflammatory cytokines in skin samples of INK4a/Arf‐/‐ mice following treatment with chronic UVB radiation. Furthermore, significantly more CD11b+Gr1+ myeloid cells were present in UVB‐exposed INK4a/Arf‐/‐ mice compared to WT mice. Our data indicate that by targeting UVB‐induced inflammation, it may be possible to prevent UVB‐induced skin tumors in individuals that carry CDKN2A mutation.
- 18 April 2017
- Published by Wiley in Experimental Dermatology
- Vol. 26 (11) , 1018-1025
Loss of INK4a/Arf gene enhances ultraviolet radiation‐induced cutaneous tumor development
The CDKN2A locus encodes for tumor suppressor genes p16INK4a and p14Arf which are frequently inactivated in human skin tumors. The purpose of this study was to determine the relationship between loss of INK4a/Arf activity and inflammation in the development of ultraviolet (UV) radiation‐induced skin tumors. Panels of INK4a/Arf‐/− mice and wild‐type (WT) mice were treated with a single dose of UVB (200 mJ/cm2). For long‐term studies, these mice were irradiated with UVB (200 mJ/cm2) three times weekly for 30 weeks. At the end of the experiment, tissues were harvested from mice and assayed for inflammatory biomarkers and cytokines. A single dose of UVB resulted in a significant increase in reactive oxygen species (ROS) and 8‐dihydroxyguanosine (8‐oxo‐dG) lesions in INK4a/Arf−/− mice compared to WT mice. When subjected to chronic UVB, we found that 100% of INK4a/Arf−/‐ mice had tumors, whereas there were no tumors in WT controls after 24 weeks of UVB exposure. The increase in tumor development correlated with a significant increase in nuclear factor (NF)‐κB, cyclooxygenase‐2 (COX‐2), prostaglandin E2 (PGE2) and its receptors both in UVB‐exposed skin and in the tumors. A significant increase was seen in inflammatory cytokines in skin samples of INK4a/Arf‐/‐ mice following treatment with chronic UVB radiation. Furthermore, significantly more CD11b+Gr1+ myeloid cells were present in UVB‐exposed INK4a/Arf‐/‐ mice compared to WT mice. Our data indicate that by targeting UVB‐induced inflammation, it may be possible to prevent UVB‐induced skin tumors in individuals that carry CDKN2A mutation.
- Open Access
- 1 October 2016
- Published by Springer Nature in 3 Biotech
- Vol. 6 (2) , 212
In vitro evaluation of anti-proliferative, anti-inflammatory and pro-apoptotic activities of the methanolic extracts of Andrographis nallamalayana Ellis on A375 and B16F10 melanoma cell lines
Natural plant products have been widely used in controlling cancer with fewer or no side effects and the use of plant extracts as complementary to synthetic medicine is gaining increased popularity. Members of Andrographis plants possess important medicinal properties. In the present study, anti-cancerous properties of Andrographis nallamalayana (AN) were tested on A375 and B16F10 skin melanoma cancer cell lines. The leaf extracts of AN significantly reduced the cell viability and cell survival of skin cancer cell lines, achieved by MTT assay and clonogenic assays, respectively. Further, TUNEL assays revealed that AN extracts induces the apoptosis. Western blot analysis revealed that AN leaf extracts reduced the expression of Bcl-2, an anti-apoptotic protein and induced the expression of proapoptotic molecules such as Bcl-2 associated death promoter protein (BAD), Bcl-2 associated X protein (BAX) and cleaved caspase-3. Moreover, the qRT-PCR and western blot analysis demonstrated the reduced expression of G2/M phase proteins cdk1, cyclin B1 and increased expression of p53, cyclin-dependent kinase 1 inhibitor, p21. Further, immunofluorescence analysis revealed that AN reduced the NF-κB nuclear translocation, luciferase reporter assays demonstrated reporter gene activation. qRT-PCR assays showed that AN significantly reduced the expression of NF-κB target genes. The results concluded that the extracts of AN exhibited significant anti-proliferative, anti-inflammatory and pro-apoptotic activities on melanoma skin cancer cell lines.
- 1 October 2016
- Published by Springer Nature in 3 Biotech
- Vol. 6 (2) , 212
Open AccessIn vitro evaluation of anti-proliferative, anti-inflammatory and pro-apoptotic activities of the methanolic extracts of Andrographis nallamalayana Ellis on A375 and B16F10 melanoma cell lines
Natural plant products have been widely used in controlling cancer with fewer or no side effects and the use of plant extracts as complementary to synthetic medicine is gaining increased popularity. Members of Andrographis plants possess important medicinal properties. In the present study, anti-cancerous properties of Andrographis nallamalayana (AN) were tested on A375 and B16F10 skin melanoma cancer cell lines. The leaf extracts of AN significantly reduced the cell viability and cell survival of skin cancer cell lines, achieved by MTT assay and clonogenic assays, respectively. Further, TUNEL assays revealed that AN extracts induces the apoptosis. Western blot analysis revealed that AN leaf extracts reduced the expression of Bcl-2, an anti-apoptotic protein and induced the expression of proapoptotic molecules such as Bcl-2 associated death promoter protein (BAD), Bcl-2 associated X protein (BAX) and cleaved caspase-3. Moreover, the qRT-PCR and western blot analysis demonstrated the reduced expression of G2/M phase proteins cdk1, cyclin B1 and increased expression of p53, cyclin-dependent kinase 1 inhibitor, p21. Further, immunofluorescence analysis revealed that AN reduced the NF-κB nuclear translocation, luciferase reporter assays demonstrated reporter gene activation. qRT-PCR assays showed that AN significantly reduced the expression of NF-κB target genes. The results concluded that the extracts of AN exhibited significant anti-proliferative, anti-inflammatory and pro-apoptotic activities on melanoma skin cancer cell lines.
- Open Access
- 23 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0155882
Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis
The most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leads to deletion of the phenylalanine at position 508 (ΔF508) in the CFTR protein and causes multiple folding and functional defects. Contrary to large-scale efforts by industry and academia, no significant therapeutic benefit has been achieved with a single “corrector”. Therefore, investigations concentrate on drug combinations. Orkambi (Vertex Pharmaceuticals), the first FDA-approved drug for treatment of cystic fibrosis (CF) caused by this mutation, is a combination of a corrector (VX-809) that facilitates ΔF508 CFTR biogenesis and a potentiator (VX-770), which improves its function. Yet, clinical trials utilizing this combination showed only modest therapeutic benefit. The low efficacy Orkambi has been attributed to VX-770-mediated destabilization of VX-809-rescued ΔF508 CFTR. Here we report that the negative effects of VX-770 can be reversed by increasing the half-life of the endoplasmic reticulum (ER) form (band B) of ΔF508 CFTR with another corrector (Corr-4a.) Although Corr-4a alone has only minimal effects on ΔF508 CFTR rescue, it increases the half-life of ΔF508 CFTR band B when it is present during half-life measurements. Our data shows that stabilization of band B ΔF508 CFTR with Corr-4a and simultaneous rescue with VX-809, leads to a >2-fold increase in cAMP-activated, CFTRinh-172-inhibited currents compared to VX-809 alone, or VX-809+VX-770. The negative effects of VX-770 and the Corr-4a protection are specific to the native I507-ATT ΔF508 CFTR without affecting the inherently more stable, synonymous variant I507-ATC ΔF508 CFTR. Our studies emphasize that stabilization of ΔF508 CFTR band B in the ER might improve its functional rescue by Orkambi.
- 23 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0155882
Open AccessMechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis
The most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leads to deletion of the phenylalanine at position 508 (ΔF508) in the CFTR protein and causes multiple folding and functional defects. Contrary to large-scale efforts by industry and academia, no significant therapeutic benefit has been achieved with a single “corrector”. Therefore, investigations concentrate on drug combinations. Orkambi (Vertex Pharmaceuticals), the first FDA-approved drug for treatment of cystic fibrosis (CF) caused by this mutation, is a combination of a corrector (VX-809) that facilitates ΔF508 CFTR biogenesis and a potentiator (VX-770), which improves its function. Yet, clinical trials utilizing this combination showed only modest therapeutic benefit. The low efficacy Orkambi has been attributed to VX-770-mediated destabilization of VX-809-rescued ΔF508 CFTR. Here we report that the negative effects of VX-770 can be reversed by increasing the half-life of the endoplasmic reticulum (ER) form (band B) of ΔF508 CFTR with another corrector (Corr-4a.) Although Corr-4a alone has only minimal effects on ΔF508 CFTR rescue, it increases the half-life of ΔF508 CFTR band B when it is present during half-life measurements. Our data shows that stabilization of band B ΔF508 CFTR with Corr-4a and simultaneous rescue with VX-809, leads to a >2-fold increase in cAMP-activated, CFTRinh-172-inhibited currents compared to VX-809 alone, or VX-809+VX-770. The negative effects of VX-770 and the Corr-4a protection are specific to the native I507-ATT ΔF508 CFTR without affecting the inherently more stable, synonymous variant I507-ATC ΔF508 CFTR. Our studies emphasize that stabilization of ΔF508 CFTR band B in the ER might improve its functional rescue by Orkambi.
- Open Access
- 3 September 2015
- Published by Wiley in The FASEB Journal
- Vol. 30 (1) , 201-213
A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator
Synonymous mutations, such as I507‐ATCÅATT, in deletion of Phe508 in cystic fibrosis transmembrane conductance regulator (ΔF508 CFTR), the most frequent disease‐associated mutant of CFTR, may affect protein biogenesis, structure, and function and contribute to an altered disease phenotype. Small‐molecule drugs are being developed to correct ΔF508 CFTR. To understand correction mechanisms and the consequences of synonymous mutations, we analyzed the effect of mechanistically distinct correctors, corrector 4a (C4) and lumacaftor (VX‐809), on I507‐ATT and I507‐ATC ΔF508 CFTR biogenesis and function. C4 stabilized I507‐ATT ΔF508 CFTR band B, but without considerable biochemical and functional correction. VX‐809 biochemically corrected ~10% of both of the variants, leading to stable, forskolin+3‐isobutyl‐1‐methylxanthine (IBMX)‐activated whole‐cell currents in the presence of the corrector. Omitting VX‐809 during whole‐cell recordings led to a spontaneous decline of the currents, suggesting posttranslational stabilization by VX‐809. Treatment of cells with the C4+VX‐809 combination resulted in enhanced rescue and 2‐fold higher forskolin+IBMX‐activated currents of both I507‐ATT and I507‐ATC ΔF508 CFTR, compared with VX‐809 treatment alone. The lack of an effect of C4 on I507‐ATC ΔF508 CFTR, but its additive effect in combination with VX‐809, implies that C4 acted on VX‐809‐modified I507‐ATC ΔF508 CFTR. Our results suggest that binding of C4 and VX‐809 to ΔF508 CFTR is conformation specific and provide evidence that synonymous mutations can alter the drug sensitivity of proteins.—Bali, V., Lazrak, A., Guroji, P., Fu, L., Matalon, S., Bebok, Z. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. FASEB J. 30, 201‐213 (2016). www.fasebj.org
- 3 September 2015
- Published by Wiley in The FASEB Journal
- Vol. 30 (1) , 201-213
Open AccessA synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator
Synonymous mutations, such as I507‐ATCÅATT, in deletion of Phe508 in cystic fibrosis transmembrane conductance regulator (ΔF508 CFTR), the most frequent disease‐associated mutant of CFTR, may affect protein biogenesis, structure, and function and contribute to an altered disease phenotype. Small‐molecule drugs are being developed to correct ΔF508 CFTR. To understand correction mechanisms and the consequences of synonymous mutations, we analyzed the effect of mechanistically distinct correctors, corrector 4a (C4) and lumacaftor (VX‐809), on I507‐ATT and I507‐ATC ΔF508 CFTR biogenesis and function. C4 stabilized I507‐ATT ΔF508 CFTR band B, but without considerable biochemical and functional correction. VX‐809 biochemically corrected ~10% of both of the variants, leading to stable, forskolin+3‐isobutyl‐1‐methylxanthine (IBMX)‐activated whole‐cell currents in the presence of the corrector. Omitting VX‐809 during whole‐cell recordings led to a spontaneous decline of the currents, suggesting posttranslational stabilization by VX‐809. Treatment of cells with the C4+VX‐809 combination resulted in enhanced rescue and 2‐fold higher forskolin+IBMX‐activated currents of both I507‐ATT and I507‐ATC ΔF508 CFTR, compared with VX‐809 treatment alone. The lack of an effect of C4 on I507‐ATC ΔF508 CFTR, but its additive effect in combination with VX‐809, implies that C4 acted on VX‐809‐modified I507‐ATC ΔF508 CFTR. Our results suggest that binding of C4 and VX‐809 to ΔF508 CFTR is conformation specific and provide evidence that synonymous mutations can alter the drug sensitivity of proteins.—Bali, V., Lazrak, A., Guroji, P., Fu, L., Matalon, S., Bebok, Z. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. FASEB J. 30, 201‐213 (2016). www.fasebj.org